ArticleJACC. Advances2026
Remote Management of Patients With Heart Failure in Medically Underserved Areas.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedically underserved areas (MUAs) are associated with higher rates of hospitalizations and mortality. Although structured remote management (RM) programs demonstrated clinical benefits, their effectiveness in MUAs in Europe remains scarcely investigated.
objectivesThe objective of the study was to assess whether heart failure (HF) patients derive similar outcomes from a structured, multiparametric, RM program irrespective of MUA designation.
methodsConsecutive patients enrolled in a standardized, multiparametric, HF RM program between April 2020 and December 2022 in 2 French regions (Auvergne Rhône-Alpes and Nouvelle-Aquitaine) at 2 French university hospitals were included in the study. Inclusion criteria were chronic HF with ≥1 episode of HF hospitalization within the last year or NYHA functional class ≥II associated with an elevated B-type natriuretic peptide. Patient assessments were performed remotely with body weight, blood pressure, heart rate, symptoms, biology, and data from cardiac implantable electronic devices. The primary outcome was the composite of unplanned HF hospitalization or all-cause mortality.
resultsAmong 1,040 patients (mean age 72 ± 12 years, 70% male), 32% lived in MUAs. The median follow-up was 20 (IQR: 10-24) months. The annualized rate of the primary outcome was 13.7% (95% CI: 11.9-15.9) in the overall population, with no significant difference between MUAs and no MUAs patients (13.5% [95% CI: 10.3-17.4] vs 13.9% [95% CI: 11.6-16.5]; P = 0.876). MUAs were not associated with the primary outcome (adjusted HR: 0.93; 95% CI: 0.68-1.27; P = 0.84). Using Kaplan-Meier analysis, survival curves showed no difference between MUA and non-MUA patients (P = 0.83).
conclusionsOur study showed no difference in primary outcome among HF patients enrolled in a structured, multiparametric RM program, irrespective of MUAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.